<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Wallace, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Involvement of the musculoskeletal system is extremely common in patients with systemic lupus erythematosus (SLE). Arthralgia, arthritis, osteonecrosis (avascular necrosis of bone), and myopathy are the principal manifestations. Osteoporosis, often due to glucocorticoid therapy, may increase the risk of fractures.</p><p>The musculoskeletal manifestations of SLE in adults are reviewed here. SLE in children and an overview of the clinical manifestations of SLE in adults are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">JOINT INVOLVEMENT</span><span class="headingEndMark"> — </span>Joint involvement is the most common feature observed in patients with systemic lupus erythematosus (SLE) and has been noted in up to 95 percent of patients [<a href="#rid1">1,2</a>]. Such symptoms are known to have a negative impact on quality of life [<a href="#rid3">3</a>]. Joint symptoms are often the first symptom of SLE and are present in approximately 75 percent of patients at the time of diagnosis [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Clinical characteristics</span><span class="headingEndMark"> — </span>The manifestations of joint involvement in patients with SLE are heterogeneous and range from mild arthralgias to more severe arthropathy [<a href="#rid2">2</a>]. Other characteristic features of the arthritis associated with SLE are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonerosive arthritis</strong> – The arthritis of SLE is typically nonerosive and is generally different from that of rheumatoid arthritis (RA)  (<a class="graphic graphic_table graphicRef54324" href="/z/d/graphic/54324.html" rel="external">table 1</a>) [<a href="#rid5">5-8</a>]. The arthritis and arthralgias of SLE tend to be migratory; symptoms in a particular joint may be gone within 24 hours but can often last longer. Although any joint can be involved, the arthritis is usually symmetric and polyarticular, with a predilection for the knees, carpal joints, and joints of the fingers, especially the proximal interphalangeal (PIP) joint. The ankles, elbows, shoulders, and hips are less frequently involved. Involvement of the sacroiliac joints and cervical spine may occur but is rare. Monoarticular arthritis is unusual and suggests an alternative cause such as infection.</p><p></p><p class="bulletIndent1">Over 25 percent of patients with SLE and joint symptoms have proven synovitis on magnetic resonance imaging (MRI) or ultrasound [<a href="#rid9">9,10</a>]. Synovial effusions are less frequent. When they occur, they are usually small, and the fluid is clear or slightly cloudy [<a href="#rid11">11</a>]. In contrast to the highly inflammatory exudates of RA, the synovial fluid in SLE is only mildly inflammatory, with low protein levels and white blood cell counts (similar to a transudate) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Although typically considered nonerosive, imaging with ultrasound or MRI has revealed that chronic synovitis and erosions in patients with SLE are more common than previously thought [<a href="#rid9">9,12,13</a>]. The presence of antibodies to citrullinated peptides/proteins in patients with SLE is associated with erosive arthritis, and are present in approximately 5 to 10 percent of patients with SLE [<a href="#rid14">14-17</a>]. This antibody profile can be observed in patients with overlapping features of both SLE and RA, which has been referred to as Rhupus. This form of SLE-related arthritis is rare and is discussed further below. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Differential diagnosis'</a> and <a class="local">'Rhupus'</a> below.)</p><p></p><p class="bulletIndent1">Synovial histopathology tends to be nonspecific, with superficial fibrin-like material and local or diffuse synovial cell lining proliferation [<a href="#rid8">8</a>]. Vascular changes have included perivascular mononuclear cells, lumen obliteration, enlarged endothelial cells, and thrombi; blood vessel fibrinoid necrosis (eg, vasculitis) is uncommon [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hand deformity</strong> – Although the arthritis of SLE is generally considered to be nondeforming, joint deformities such as ulnar deviation, thumb subluxation, and boutonniere and swan neck deformities, as seen in RA, have been noted in 15 to 50 percent of patients with SLE [<a href="#rid5">5-8,19,20</a>]. These deformities, referred to as Jaccoud arthropathy, are typically easily reducible; they are thought to be due to lax joint capsules, tendons, and ligaments that cause joint instability. Risk factors for joint deformity include treatment with glucocorticoids, presence of anti-Ro/SSA and/or anti-La/SSB antibodies [<a href="#rid21">21</a>], or longstanding disease [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tendinopathy</strong> – Tenosynovitis has been noted in 10 to 44 percent of patients, including epicondylitis, rotator cuff tendinitis, Achilles tendinitis, tibialis posterior tendinitis, and plantar fasciitis [<a href="#rid8">8,19,22,23</a>]. Infrapatellar and Achilles tendon ruptures are rare [<a href="#rid24">24</a>].</p><p></p><p>Pain from arthralgias/arthritis must be distinguished from fibromyalgia, which is common among patients with SLE (see <a class="local">'Fibromyalgia'</a> below). The arthritis in patients with SLE must also be distinguished from osteoarthritis and RA. (See <a class="local">'Rhupus'</a> below.)</p><p>The approach to diagnostic imaging for polyarticular joint pain and the utility of various imaging modalities for joint pain are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain"</a> and  <a class="medical medical_review" href="/z/d/html/6921.html" rel="external">"Imaging techniques for evaluation of the painful joint"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Treatment of arthritis</span><span class="headingEndMark"> — </span>Arthralgias and arthritis associated with SLE typically respond to the use of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> alone. Short courses of nonsteroidal antiinflammatory drugs (NSAIDs) may occasionally be needed to control symptoms but should be used cautiously especially if the patient also has kidney involvement.</p><p>Some patients may demonstrate features of a more severe or persistent arthritis, and additional immunosuppressive therapy may be needed. Our approach to managing such patients is described further below. (See <a class="local">'Mild to moderate symptoms'</a> below and <a class="local">'Persistent or severe symptoms'</a> below.)</p><p class="headingAnchor" id="H2474782794"><span class="h3">Mild to moderate symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> – All patients with SLE should be initiated on hydroxychloroquine at the time of their diagnosis with SLE, unless otherwise contraindicated. Hydroxychloroquine has been shown to be effective for the amelioration of joint symptoms, as well as for the prevention of disease flares, of damage accrual, and for delaying mortality [<a href="#rid25">25-32</a>]. We use hydroxychloroquine, typically dosed at 200 to 400 mg/day with adjustments based on body weight (the dose should not exceed 5 mg/kg of real [actual] body weight/day) or blood level (within the therapeutic range) to avoid retinal toxicity. We typically counsel patients that the effect on joint symptoms is not observed until two to three months after initiation of hydroxychloroquine. The role of hydroxychloroquine in the management of SLE is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a>.)</p><p></p><p class="bulletIndent1">There are limited data regarding the efficacy of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> for the treatment of arthritis associated with SLE. In a trial including 71 patients with SLE and arthritis and arthralgias, patients randomly assigned to receive hydroxychloroquine experienced a greater improvement in subjective joint pain at 48 weeks of follow-up compared with placebo [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs</strong> – For patients with persistent joint pain while on antimalarials, we suggest oral nonsteroidal antiinflammatory drugs (NSAIDs) for symptomatic relief of arthritic pain rather than glucocorticoids, preferably at the lowest dose and shortest duration possible [<a href="#rid33">33</a>]. Topical <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> may be used for patients with hand and knee pain who want to limit the systemic side effects of oral NSAIDs. Our approach to using NSAIDs for symptomatic relief of RA symptoms is presented separately (see  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'NSAIDs'</a>). Alternatively, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (up to 3 g/day in the absence of liver disease or alcohol abuse) may be used if NSAIDs are contraindicated, not tolerated, or ineffective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic therapies – </strong>Patients with arthritis related to SLE may benefit from the addition of nonpharmacologic therapies similar to those used to treat other forms of inflammatory arthritis, including use of assistive devices and referral to physical or occupational therapy. Nonpharmacologic therapy for arthralgia and arthritis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7498.html" rel="external">"Nonpharmacologic therapies for patients with rheumatoid arthritis", section on 'Physical and occupational therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7754.html" rel="external">"Overview of joint protection"</a>.)</p><p></p><p class="headingAnchor" id="H527225531"><span class="h3">Persistent or severe symptoms</span><span class="headingEndMark"> — </span>Patients with more persistent or severe arthritic and/or inflammatory symptoms may require additional immunosuppressive therapy. This may include some patients with Rhupus, which is a term that describes patients with overlapping features of SLE and RA and is discussed further below. (See <a class="local">'Rhupus'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – For patients with persistent joint pain secondary to arthritis that has not resolved while on antimalarials and NSAIDs, or for whom NSAIDs are contraindicated, we suggest a short course of glucocorticoids rather than continuing NSAIDs. Based upon our clinical experience, we usually initiate therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 to 20 mg/day, depending upon the severity of joint inflammation and upon the minimal dose required to obtain initial control. However, patients with concomitant systemic flares may require higher doses of glucocorticoids to control other disease manifestations. If courses of glucocorticoids longer than two to four weeks are required to control isolated arthritis symptoms, an alternative immunosuppressive therapy or disease-modifying antirheumatic drug (DMARD) should be added so that the glucocorticoid can be tapered. NSAIDs and glucocorticoids should not be used at the same time due to the increased risk of adverse gastrointestinal events. (See  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – For patients with SLE and persistent arthritis while on antimalarials, or an arthritis that is requiring courses of glucocorticoids longer than two to four weeks, we suggest adding methotrexate to avoid the need for glucocorticoids while controlling joint disease. Patients unable to tolerate or take methotrexate can try <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> as an alternative unless otherwise contraindicated [<a href="#rid34">34,35</a>]. However, both methotrexate and leflunomide are teratogenic and contraindicated in women who are pregnant or contemplating becoming pregnant. There are limited data regarding the use of methotrexate or leflunomide for arthritis associated with SLE, and this approach is largely based on indirect evidence from the treatment of RA. A systematic review of nine studies (three of which were randomized controlled trials) including patients with SLE with predominantly mucocutaneous or arthritis features found that methotrexate use was associated with a statistically significant reduction in disease activity as well as the average dose of glucocorticoids used by patients [<a href="#rid36">36</a>]. Methotrexate and leflunomide are dosed in the same manner as that used for RA. (See  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Initial therapy with methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Alternatives to methotrexate'</a>.)</p><p></p><p>For patients with persistent arthritis unresponsive to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> after three to six months of therapy, the choice of subsequent agent depends on several factors including considerations regarding other disease manifestations, comorbidities, cost of treatments, and availability of specific agents. <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a> and <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">anifrolumab</a> may be preferable for patients with SLE with predominantly both skin and joint manifestations. Other options include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, as well as other agents typically used to treat RA (eg, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, janus kinase inhibitors, and tumor necrosis factor [TNF] inhibitors). Available data regarding the use of these agents for patients with SLE and arthritis are limited:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a> – Belimumab, a human monoclonal antibody that inhibits the soluble form of a B-cell survival factor (known as B lymphocyte stimulator [BLyS] or B-cell activating factor [BAFF]), appears to be useful for patients with joint and skin manifestations of SLE. The pivotal trials for belimumab demonstrated improvements in musculoskeletal outcomes in patients with SLE [<a href="#rid37">37,38</a>]. Post hoc analyses have further examined the results of these trials, and reported benefits include decreased musculoskeletal and mucocutaneous involvement and decreased requirements for glucocorticoids [<a href="#rid39">39-43</a>]. A Cochrane review including six randomized trials found that belimumab alone or in combination with other immunosuppressive drugs in patients with SLE (but not active nephritis or central nervous system involvement) resulted in reduced disease activity as measured by a validated disease activity score, with an absolute risk difference of 13 percent improvement (95% CI 8-17 percent) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">Anifrolumab</a> – Anifrolumab, a type I interferon receptor antagonist (immunoglobulin [Ig] G1 kappa monoclonal antibody), may be used as an alternative to <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a> for patients with persistent joint symptoms, although more data are needed to determine its role in therapy. The use of anifrolumab for patients with SLE is based on data from three randomized trials in which patients with SLE demonstrated improvement in composite indices of disease activity and/or a reduction in glucocorticoid dose [<a href="#rid45">45-47</a>]. The trials included patients classified as having moderate to severe SLE despite standard therapies, but patients with manifestations of severe lupus nephritis or neuropsychiatric disease were excluded. These trials are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults"</a>.)</p><p></p><p class="bulletIndent1">A post hoc analysis of pooled data from one of the pivotal randomized trials suggests that <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">anifrolumab</a> may be most effective for patients specifically with joint and skin involvement of SLE [<a href="#rid48">48</a>]. At 52 weeks, a greater percentage of patients receiving anifrolumab (56.7 percent) demonstrated a near complete resolution of arthritis as defined by Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K) when compared with placebo (42.6 percent; odds ratio [OR] 1.88 [90% CI 1.16-3.04]). Findings related to arthritis were also more favorable for the anifrolumab group when compared with placebo as measured by the British Isles Lupus Assessment Group (BILAG; 69.1 versus 49.5 percent; OR 2.47 [90% CI 1.48-4.12]), as well as for the swollen and tender joint counts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> – The efficacy of azathioprine in controlling SLE-associated arthritis is extrapolated from results of RA trials. Also, azathioprine has been shown to decrease activity of nonrenal manifestations, which include patients with SLE and musculoskeletal manifestations such as arthritis [<a href="#rid49">49-51</a>]. Information regarding dosing, monitoring, and adverse effects of azathioprine can be found separately. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – The use of rituximab is largely based on observational studies showing a reduction in disease activity with rituximab [<a href="#rid52">52-54</a>]. Additional information regarding dosing and adverse effects of rituximab can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – Other agents including <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> and janus kinase inhibitors (eg, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>) also used for the treatment of RA can also improve the arthritis associated with SLE and have been found to be safe [<a href="#rid55">55-58</a>]. Although TNF inhibitors are known to induce antinuclear antibodies and, less commonly, lead to drug-induced SLE, they are not contraindicated in patients with SLE. However, in our experience, TNF inhibitors are of little benefit in patients with SLE, with the exception of those whose arthritis is more consistent with Rhupus. (See <a class="local">'Rhupus'</a> below and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'JAK inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'TNF inhibitors'</a>.)</p><p></p><p>Total joint arthroplasty is sometimes required in patients with SLE. In one cohort of 500 patients with SLE followed at a single center in Great Britain, arthritis was present in 94 percent, but only 4 percent (19 patients) underwent at least one total joint replacement between 1978 and 2008 [<a href="#rid59">59</a>]. The findings most often associated with undergoing joint replacement were osteonecrosis and overlapping features of RA (in 10 and 11 patients, respectively). An analysis of data from a large hospitalization database in the United States suggested that patients with SLE are at increased risk for postoperative mortality after joint arthroplasty [<a href="#rid60">60</a>]. However, pain and functional outcomes of arthroplasty appear to be comparable with those of the general population undergoing arthroplasty for osteoarthritis [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1297876369"><span class="h1">BONE INVOLVEMENT</span></p><p class="headingAnchor" id="H7"><span class="h2">Osteonecrosis</span><span class="headingEndMark"> — </span>Asymptomatic osteonecrosis (also called avascular, aseptic, or ischemic necrosis) has been reported in up to one-third of patients with systemic lupus erythematosus (SLE) [<a href="#rid62">62,63</a>]. Estimates of the prevalence of symptomatic osteonecrosis are lower and closer to approximately 10 percent [<a href="#rid64">64</a>]. Although the femoral head is the most common site for osteonecrosis, the humeral head, tibial plateau, and scaphoid (navicular) can also be affected [<a href="#rid5">5,65-67</a>]. Osteonecrosis is usually bilateral and is often asymptomatic. When symptoms occur, femoral head involvement usually manifests as pain in the groin, especially with weightbearing. The clinical manifestations and diagnosis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">"Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)"</a>.)</p><p>Risk factors for osteonecrosis among patients with SLE include treatment with glucocorticoids and disease activity [<a href="#rid67">67-69</a>]. The risk of glucocorticoids and other factors leading to the development of osteonecrosis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">"Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">"Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)", section on 'Risk factors'</a>.)</p><p>The management of osteonecrosis is the same as for those without SLE. Patients with SLE who require total hip or knee arthroplasties typically do as well as those without SLE [<a href="#rid61">61,70,71</a>]. The approach to therapy of osteonecrosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5613.html" rel="external">"Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Several population-based studies have reported a higher prevalence of osteoporosis among patients with SLE compared with the general population [<a href="#rid72">72,73</a>]. The risk of hip and vertebral fracture are almost two- and threefold higher, respectively, when compared with the general population [<a href="#rid74">74,75</a>]. In addition to conventional risk factors for osteoporosis (eg, age, postmenopausal status), other risks factors in patients with SLE include use of glucocorticoids, high disease activity, and renal failure [<a href="#rid76">76-79</a>]. Decreased serum 25-hydroxyvitamin D levels are more common among patients with SLE compared with healthy subjects [<a href="#rid80">80</a>]. In addition, low 25-hydroxyvitamin D levels appear to be associated with increased disease activity in patients with SLE [<a href="#rid81">81</a>]. Thus, vitamin D monitoring with supplementation when needed should be part of routine management. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p>Certain general principles should be followed in all patients to minimize bone loss, particularly in patients receiving therapy with glucocorticoids. The treatment of osteoporosis and prevention of glucocorticoid-induced osteoporosis are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>Briefly, important elements in management include:</p><p class="bulletIndent1"><span class="glyph">●</span>Modification of lifestyle factors (ie, elimination of cigarette smoking, limitation of alcohol consumption, and maintenance of a weightbearing exercise regimen). (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'General measures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limitation of glucocorticoid therapy to the lowest possible dose and duration required. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'General measures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of calcium and vitamin D. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Calcium and vitamin D'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of bone mineral density and administration of pharmacologic therapy when needed. Other aspects of osteoporosis are discussed elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Fractures</span><span class="headingEndMark"> — </span>The risk of fracture in patients with SLE is five times that of the general population [<a href="#rid82">82,83</a>]. Osteopenia and osteoporosis may account for much of the increased risk (see <a class="local">'Osteoporosis'</a> above). The magnitude of the fracture risk is illustrated by a cohort study of approximately 700 women with SLE and an equivalent number of age-matched controls; a fivefold increase in fracture among those with SLE was noted [<a href="#rid82">82</a>]. Variables that were significantly associated with the time from diagnosis to that of fracture included older age at the time of diagnosis of SLE, longer disease duration, longer duration of glucocorticoid use, less use of oral contraceptives, and menopause status. Vertebral fractures, found in up to 20 percent of patients with SLE, have been associated with intravenous use of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> at any time and with male sex [<a href="#rid84">84</a>].</p><p>The presence of antiphospholipid antibodies (aPL) may be associated with an increased risk of nontraumatic fractures. This was illustrated in one study that linked aPL to an increased risk of metatarsal (stress) fractures in patients with SLE [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H13"><span class="h1">MUSCLE INVOLVEMENT</span><span class="headingEndMark"> — </span>Myalgias, muscle tenderness, or muscle weakness occurs in up to 70 percent of patients with systemic lupus erythematosus (SLE) and may be the reason that the patient initially seeks medical attention [<a href="#rid5">5,86-88</a>]. However, severe muscle weakness, atrophy, or myositis is relatively uncommon (7 to 15 percent) [<a href="#rid5">5,89,90</a>]. Pathologic examination reveals perivascular and perifascicular mononuclear cell infiltrates in 25 percent of patients [<a href="#rid22">22</a>]. Other histologic findings include muscle atrophy, microtubular inclusions, mononuclear infiltrate, fiber necrosis, and, occasionally, vacuolated muscle fibers [<a href="#rid91">91</a>]. Significant elevations in creatinine kinase (CK) (eg, ≥500 units/L) are rare, occurring in less than 5 percent of patients with SLE, and may suggest an overlap syndrome [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">"Mixed connective tissue disease", section on 'Musculoskeletal'</a>.)</p><p>In addition to SLE itself, rarely, glucocorticoids and antimalarial drugs can cause muscle weakness [<a href="#rid86">86,87</a>]. Medication-induced myopathy is generally easily differentiated from SLE-induced myopathy or myositis:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum levels of CK and/or aldolase are usually normal in patients with glucocorticoid-induced myopathy, although lactate dehydrogenase (LDH) values may be elevated in some cases [<a href="#rid93">93</a>]. Muscle biopsy reveals an increase in the number of sarcolemmal nuclei, rowing and centralization of the nuclei, vacuolization and loss of fiber cross-striations, and phagocytosis, but does not reveal the inflammation characteristic of SLE [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle enzymes are also typically normal in patients with antimalarial-induced myopathy. Muscle biopsy may reveal vacuolar changes but not inflammation.</p><p></p><p>Establishing the correct diagnosis has important implications for therapy. Lupus myositis responds to treatment with glucocorticoids (using a regimen similar to that in polymyositis), while glucocorticoid-induced myopathy responds to a reduction in or withdrawal of glucocorticoid therapy. Antimalarial myopathy responds to stopping the drug, but it may take months for the myopathy to improve, partly due to the months-long half-life of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>. (See  <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">"Glucocorticoid-induced myopathy"</a> and  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p>Other medications that may also cause myopathy, most often resulting in myalgias but also more severe muscle disease, include statins being used for treatment of hyperlipidemia. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p class="headingAnchor" id="H67237527"><span class="h1">COMORBID AND OVERLAP CONDITIONS</span></p><p class="headingAnchor" id="H14"><span class="h2">Fibromyalgia</span><span class="headingEndMark"> — </span>Reported prevalence rates of fibromyalgia in patients with systemic lupus erythematosus (SLE) vary widely (from 20 to 40 percent) but in general, are much higher than in the general population [<a href="#rid95">95,96</a>]. The symptoms are detrimental to the patient's quality of life and may increase disability [<a href="#rid97">97</a>]. The diagnosis of fibromyalgia may be challenging in the setting of SLE, particularly among patients with fatigue and pain. (See  <a class="medical medical_review" href="/z/d/html/5624.html" rel="external">"Clinical manifestations and diagnosis of fibromyalgia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5627.html" rel="external">"Treatment of fibromyalgia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/118590.html" rel="external">"Overview of chronic widespread (centralized) pain in the rheumatic diseases", section on 'Systemic lupus erythematosus and Sjögren's disease'</a>.)</p><p class="headingAnchor" id="H3941081434"><span class="h2">Rhupus</span><span class="headingEndMark"> — </span>The term "Rhupus" has traditionally been used to describe patients with overlapping features of both SLE and rheumatoid arthritis (RA) [<a href="#rid98">98,99</a>]. Whether Rhupus is clinically and immunologically a distinct entity, a true overlap of SLE and RA, or a subset of patients with SLE remains a matter of debate. The main feature of Rhupus is an RA-like arthritis that must be differentiated from the more common nonerosive and nondeforming arthritis observed in SLE. Also, when compared with patients with SLE, patients with Rhupus tend to have lower disease activity scores and are less likely to have severe organ involvement (eg, kidney involvement and hematologic abnormalities) [<a href="#rid100">100,101</a>]. Subcutaneous nodules that occur characteristically in patients with RA have been noted in patients with Rhupus [<a href="#rid5">5,102</a>]. Among patients with Rhupus, the prevalence of rheumatoid factor and anti-cyclic citrullinated peptide antibodies is higher compared with patients with SLE [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"</a>.)</p><p>The treatment of the joint disease associated with Rhupus is largely extrapolated from the management of RA. Management may include use of disease-modifying antirheumatic drugs (DMARDs) as described above. (See <a class="local">'Treatment of arthritis'</a> above.)</p><p class="headingAnchor" id="H499515"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal system involvement in SLE</strong> – Different aspects of the musculoskeletal system are often affected by systemic lupus erythematosus (SLE), with arthralgias and arthritis being among the most common. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint involvement</strong> – Arthritis and arthralgias have been noted in up to 95 percent of patients of patients with SLE and are often present in most patients at the time of diagnosis. The arthritis tends to be migratory, and in contrast to rheumatoid arthritis (RA), plain radiographic evidence of erosions is rare. (See <a class="local">'Clinical characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of arthritis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate symptoms</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All patients with SLE should be initiated on <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> at the time of their diagnosis with SLE, unless otherwise contraindicated. Hydroxychloroquine has been shown to be effective for the amelioration of joint symptoms as well as for the prevention of disease flares. Arthralgias and arthritis associated with SLE typically respond to the use of hydroxychloroquine alone. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'</a> and <a class="local">'Mild to moderate symptoms'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with persistent joint pain while on antimalarials, we suggest oral nonsteroidal antiinflammatory drugs (NSAIDs) for symptomatic relief of arthritic pain rather than glucocorticoids, preferably at the lowest dose and shortest duration possible (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild to moderate symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent or severe symptoms</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with persistent joint pain secondary to arthritis that has not resolved while on antimalarials and NSAIDs, or for whom NSAIDs are contraindicated, we suggest a short course of glucocorticoids rather than continuing NSAIDs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with SLE and persistent arthritis while on antimalarials, or an arthritis that is requiring courses of glucocorticoids longer than two to four weeks, we suggest adding <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with persistent arthritis unresponsive to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> after three to six months of therapy, the choice of subsequent agent depends on several factors including considerations regarding other disease manifestations, comorbidities, cost of treatments, and availability of specific agents. <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a> and <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">anifrolumab</a> may be preferable for patients with predominantly both skin and joint manifestations. Other options include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, as well as other agents typically used to treat RA (eg, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, janus kinase inhibitors, and tumor necrosis factor [TNF] inhibitors). (See <a class="local">'Treatment of arthritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteonecrosis</strong> – Asymptomatic osteonecrosis (also called avascular, aseptic, or ischemic necrosis) has been reported in up to one-third of patients with SLE, whereas estimates of symptomatic osteonecrosis are lower and closer to 10 percent. Risk factors include treatment with glucocorticoids and disease activity. The management of osteonecrosis is the same as for those without SLE. (See <a class="local">'Osteonecrosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoporosis</strong> – Rates of osteoporosis among patients with SLE are higher compared with the general population. In addition to conventional risk factors for osteoporosis (eg, age, postmenopausal status), other risk factors in patients with SLE include use of glucocorticoids, high disease activity, and renal failure. Thus, attention to bone health is important in the management of patients with SLE. (See <a class="local">'Osteoporosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle involvement</strong> – Myalgias, muscle tenderness, or muscle weakness occur in up to 70 percent of patients with SLE and may be the reason that the patient initially seeks medical attention. However, severe muscle weakness, atrophy, or myositis is relatively uncommon. (See <a class="local">'Muscle involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid and overlap conditions</strong> – The reported prevalence rates of fibromyalgia in patients with SLE are much higher than in the general population. "Rhupus," a term traditionally used to describe patients with overlapping features of both SLE and RA, must be differentiated from the more common nonerosive and nondeforming arthritis observed in SLE. (See <a class="local">'Comorbid and overlap conditions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.</a></li><li><a class="nounderline abstract_t">Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum 2017; 47:53.</a></li><li><a class="nounderline abstract_t">Natalucci F, Ceccarelli F, Cipriano E, et al. Joint involvement influences quality of life in systemic lupus erythematosus patients. Lupus 2021; 30:478.</a></li><li><a class="nounderline abstract_t">Urowitz MB, Gladman DD, Ibañez D, et al. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol 2014; 41:875.</a></li><li class="breakAll">Hinojosa-Azaola A, Sánchez-Guerrero J. Overview and clinical presentation. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace DJ, Hahn BH (Eds), Elsevier, 2019. p.389.</li><li><a class="nounderline abstract_t">Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14:99.</a></li><li><a class="nounderline abstract_t">van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998; 57:540.</a></li><li><a class="nounderline abstract_t">Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol 2009; 23:495.</a></li><li><a class="nounderline abstract_t">Zayat AS, Mahmoud K, Md Yusof MY, et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford) 2019; 58:304.</a></li><li><a class="nounderline abstract_t">Lins CF, Santiago MB. Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review. Eur Radiol 2015; 25:2688.</a></li><li><a class="nounderline abstract_t">Pekin TJ Jr. Zvaifler NJ: Synovial fluid findings in systemic lupus erythematosus (SLE). Arthritis Rheum 1970; 13:777.</a></li><li><a class="nounderline abstract_t">Mahmoud K, Zayat AS, Yusof Y, et al. Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. Rheumatology (Oxford) 2019; 58:1353.</a></li><li><a class="nounderline abstract_t">Tani C, D'Aniello D, Possemato N, et al. MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects. Skeletal Radiol 2015; 44:261.</a></li><li><a class="nounderline abstract_t">Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35:77.</a></li><li><a class="nounderline abstract_t">Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009; 36:2682.</a></li><li><a class="nounderline abstract_t">Budhram A, Chu R, Rusta-Sallehy S, et al. Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 2014; 23:1156.</a></li><li><a class="nounderline abstract_t">Taraborelli M, Inverardi F, Fredi M, et al. Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? Reumatismo 2012; 64:321.</a></li><li><a class="nounderline abstract_t">Labowitz R, Schumacher HR Jr. Articular manifestations of systemic lupus erythematosus. Ann Intern Med 1971; 74:911.</a></li><li><a class="nounderline abstract_t">Ostendorf B, Scherer A, Specker C, et al. Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum 2003; 48:157.</a></li><li><a class="nounderline abstract_t">Uslu S, Inel TY, Salbaş ÇS. Jaccoud arthropathy in a patient with rhupus. Clin Rheumatol 2021; 40:423.</a></li><li><a class="nounderline abstract_t">Franceschini F, Cretti L, Quinzanini M, et al. Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La. Lupus 1994; 3:419.</a></li><li class="breakAll">Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.</li><li class="breakAll">Buyon JP, Zuckerman JD. Articular manifestations of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Lahita RG (Ed), John Wiley and Sons, New York 1987.</li><li><a class="nounderline abstract_t">Morgan J, McCarty DJ. Tendon ruptures in patients with systemic lupus erythematosus treated with corticosteroids. Arthritis Rheum 1974; 17:1033.</a></li><li><a class="nounderline abstract_t">Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457.</a></li><li><a class="nounderline abstract_t">Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.</a></li><li><a class="nounderline abstract_t">Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.</a></li><li><a class="nounderline abstract_t">Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66:1168.</a></li><li><a class="nounderline abstract_t">Shinjo SK, Bonfá E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62:855.</a></li><li><a class="nounderline abstract_t">Fessler BJ, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52:1473.</a></li><li><a class="nounderline abstract_t">Pons-Estel GJ, Alarcón GS, McGwin G Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61:830.</a></li><li><a class="nounderline abstract_t">Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11:340.</a></li><li><a class="nounderline abstract_t">Tam LS, Li EK, Wong CK, et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 2006; 65:417.</a></li><li><a class="nounderline abstract_t">Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10:480.</a></li><li><a class="nounderline abstract_t">Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 2014; 23:225.</a></li><li><a class="nounderline abstract_t">Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.</a></li><li><a class="nounderline abstract_t">Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918.</a></li><li><a class="nounderline abstract_t">van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343.</a></li><li><a class="nounderline abstract_t">Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71:1833.</a></li><li><a class="nounderline abstract_t">Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:2328.</a></li><li><a class="nounderline abstract_t">Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22:63.</a></li><li><a class="nounderline abstract_t">Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol 2015; 42:2288.</a></li><li><a class="nounderline abstract_t">Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev 2021; 2:CD010668.</a></li><li><a class="nounderline abstract_t">Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol 2017; 69:376.</a></li><li><a class="nounderline abstract_t">Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019; 1:e208.</a></li><li><a class="nounderline abstract_t">Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382:211.</a></li><li><a class="nounderline abstract_t">Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med 2018; 5:e000284.</a></li><li><a class="nounderline abstract_t">Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83:597.</a></li><li><a class="nounderline abstract_t">Oelzner P, Abendroth K, Hein G, Stein G. Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Rheumatol Int 1996; 16:133.</a></li><li><a class="nounderline abstract_t">Ginzler EM, Wofsy D, Isenberg D, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62:211.</a></li><li><a class="nounderline abstract_t">Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2014; 44:175.</a></li><li><a class="nounderline abstract_t">Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61:482.</a></li><li><a class="nounderline abstract_t">McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford) 2018; 57:470.</a></li><li><a class="nounderline abstract_t">Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:3077.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis 2017; 76:534.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392:222.</a></li><li><a class="nounderline abstract_t">Lee YH, Song GG. Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials. Lupus 2023; 32:1493.</a></li><li><a class="nounderline abstract_t">Mourão AF, Amaral M, Caetano-Lopes J, Isenberg D. An analysis of joint replacement in patients with systemic lupus erythematosus. Lupus 2009; 18:1298.</a></li><li><a class="nounderline abstract_t">Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol 2010; 37:1467.</a></li><li><a class="nounderline abstract_t">Kasturi S, Goodman S. Current Perspectives on Arthroplasty in Systemic Lupus Erythematosus: Rates, Outcomes, and Adverse Events. Curr Rheumatol Rep 2016; 18:59.</a></li><li><a class="nounderline abstract_t">Ehmke TA, Cherian JJ, Wu ES, et al. Treatment of osteonecrosis in systemic lupus erythematosus: a review. Curr Rheumatol Rep 2014; 16:441.</a></li><li><a class="nounderline abstract_t">Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol 2017; 35:700.</a></li><li><a class="nounderline abstract_t">Ersin M, Demirel M, Ekinci M, et al. Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course. Lupus 2021; 30:1603.</a></li><li><a class="nounderline abstract_t">Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1986; 29:1177.</a></li><li><a class="nounderline abstract_t">Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978; 138:750.</a></li><li><a class="nounderline abstract_t">Calvo-Alén J, McGwin G, Toloza S, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 2006; 65:785.</a></li><li><a class="nounderline abstract_t">Fialho SC, Bonfá E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 2007; 16:239.</a></li><li><a class="nounderline abstract_t">Kallas R, Li J, Petri M. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study. Arthritis Care Res (Hoboken) 2022; 74:1122.</a></li><li><a class="nounderline abstract_t">Zangger P, Gladman DD, Urowitz MB, Bogoch ER. Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus. J Rheumatol 2000; 27:919.</a></li><li><a class="nounderline abstract_t">Shah UH, Mandl LA, Mertelsmann-Voss C, et al. Systemic lupus erythematosus is not a risk factor for poor outcomes after total hip and total knee arthroplasty. Lupus 2015; 24:900.</a></li><li><a class="nounderline abstract_t">Jung JY, Choi ST, Park SH, et al. Prevalence of osteoporosis in patients with systemic lupus erythematosus: A multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria. Osteoporos Sarcopenia 2020; 6:173.</a></li><li><a class="nounderline abstract_t">Salman-Monte TC, Torrente-Segarra V, Muñoz-Ortego J, et al. Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region. Rheumatol Int 2015; 35:509.</a></li><li><a class="nounderline abstract_t">Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int 2016; 27:1413.</a></li><li><a class="nounderline abstract_t">Li L, Xie H, Lu N, et al. Impact of Systemic Lupus Erythematosus on the Risk of Newly Diagnosed Hip Fracture: A General Population-Based Study. Arthritis Care Res (Hoboken) 2021; 73:259.</a></li><li><a class="nounderline abstract_t">Pineau CA, Urowitz MB, Fortin PJ, et al. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 2004; 13:436.</a></li><li><a class="nounderline abstract_t">Almehed K, Forsblad d'Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford) 2007; 46:1185.</a></li><li><a class="nounderline abstract_t">Panopalis P, Yazdany J. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11:177.</a></li><li><a class="nounderline abstract_t">Zhu TY, Griffith JF, Au SK, et al. Bone mineral density change in systemic lupus erythematosus: a 5-year followup study. J Rheumatol 2014; 41:1990.</a></li><li><a class="nounderline abstract_t">Islam MA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev 2019; 18:102392.</a></li><li><a class="nounderline abstract_t">Correa-Rodríguez M, Pocovi-Gerardino G, Callejas-Rubio JL, et al. Vitamin D Levels are Associated with Disease Activity and Damage Accrual in Systemic Lupus Erythematosus Patients. Biol Res Nurs 2021; 23:455.</a></li><li><a class="nounderline abstract_t">Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42:882.</a></li><li><a class="nounderline abstract_t">Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 2007; 34:2018.</a></li><li><a class="nounderline abstract_t">Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:2044.</a></li><li><a class="nounderline abstract_t">Sangle S, D'Cruz DP, Khamashta MA, Hughes GR. Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis 2004; 63:1241.</a></li><li class="breakAll">Stevens MB. Musculoskeletal Manifestations. In: The Clinical Management of Systemic Lupus Erythematosus, Schur, PH (Eds), Grune and Stratton, New York 1983.</li><li><a class="nounderline abstract_t">Isenber DA, Snaith ML. Muscle Disease in systemic lupus erythematosus: a study of its nature, frequency and cause. J Rheumatol 1981; 8:917.</a></li><li><a class="nounderline abstract_t">Greco CM, Rudy TE, Manzi S. Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory. Pain Med 2003; 4:39.</a></li><li class="breakAll">Ropes MW. Systemic lupus erythematosus, Harvard University Press, Cambridge 1976.</li><li><a class="nounderline abstract_t">Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus 2020; 29:776.</a></li><li><a class="nounderline abstract_t">Finol HJ, Montagnani S, Márquez A, et al. Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus. J Rheumatol 1990; 17:210.</a></li><li class="breakAll">Nacarra SV, Torralba TP. The musculoskeletal system and bone metabolism. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace DJ, Hahn BH (Eds), Elsevier, 2018. p.407.</li><li><a class="nounderline abstract_t">Kanayama Y, Shiota K, Horiguchi T, et al. Correlation between steroid myopathy and serum lactic dehydrogenase in systemic lupus erythematosus. Arch Intern Med 1981; 141:1176.</a></li><li><a class="nounderline abstract_t">Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968; 123:158.</a></li><li><a class="nounderline abstract_t">Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1181.</a></li><li><a class="nounderline abstract_t">Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, et al. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clin Exp Rheumatol 2016; 34:S40.</a></li><li><a class="nounderline abstract_t">Kiani AN, Strand V, Fang H, et al. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2013; 52:1651.</a></li><li><a class="nounderline abstract_t">Tani C, D'Aniello D, Delle Sedie A, et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 2013; 12:537.</a></li><li><a class="nounderline abstract_t">Antonini L, Le Mauff B, Marcelli C, et al. Rhupus: a systematic literature review. Autoimmun Rev 2020; 19:102612.</a></li><li><a class="nounderline abstract_t">Li J, Wu H, Huang X, et al. Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case-control study. Medicine (Baltimore) 2014; 93:e49.</a></li><li><a class="nounderline abstract_t">Liu T, Li G, Mu R, et al. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients. Lupus 2014; 23:958.</a></li><li><a class="nounderline abstract_t">Hahn BH, Yardley JH, Stevens MB. "Rheumatoid" nodules in systemic lupus erythematosus. Ann Intern Med 1970; 72:49.</a></li></ol></div><div id="topicVersionRevision">Topic 4673 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479324" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28465078" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33323011" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Joint involvement influences quality of life in systemic lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24692526" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24692526" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3041493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Musculoskeletal manifestations of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849313" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19591780" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lupus arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30265343" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716942" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5495390" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Zvaifler NJ: Synovial fluid findings in systemic lupus erythematosus (SLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30608614" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25341505" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085741" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884269" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990382" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23256108" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4931742" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Articular manifestations of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528115" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822058" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Jaccoud arthropathy in a patient with rhupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841997" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841997" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841997" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4433351" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tendon ruptures in patients with systemic lupus erythematosus treated with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7983646" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8153401" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antimalarial agents and lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984192" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103632" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389655" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131238" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880829" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479701" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12139371" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16474039" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480845" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399812" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296403" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127708" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22337213" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550315" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22275291" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263865" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26523030" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631841" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Belimumab for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28130918" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anifrolumab, an Anti-Interferon-αReceptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38229377" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Trial of Anifrolumab in Active Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30588322" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1106277" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961376" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039429" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24830791" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333973" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29216396" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533545" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27672124" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30043749" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37853751" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850657" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An analysis of joint replacement in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472923" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27443850" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Current Perspectives on Arthroplasty in Systemic Lupus Erythematosus: Rates, Outcomes, and Adverse Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25074031" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of osteonecrosis in systemic lupus erythematosus: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240590" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259056" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3768054" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The early diagnosis of ischemic necrosis of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646538" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269429" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17439929" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33342072" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782816" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595621" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Systemic lupus erythematosus is not a risk factor for poor outcomes after total hip and total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426305" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prevalence of osteoporosis in patients with systemic lupus erythematosus: A multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25030324" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26753541" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31758639" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Impact of Systemic Lupus Erythematosus on the Risk of Newly Diagnosed Hip Fracture: A General Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15303570" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17500075" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prevalence and risk factors of osteoporosis in female SLE patients-extended report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19604461" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bone health in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24986848" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bone mineral density change in systemic lupus erythematosus: a 5-year followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31520805" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33380211" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vitamin D Levels are Associated with Disease Activity and Damage Accrual in Systemic Lupus Erythematosus Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323443" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17787041" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Self-reported fractures and associated factors in women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986345" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361379" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361379" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7328567" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Muscle Disease in systemic lupus erythematosus: a study of its nature, frequency and cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873277" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873277" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281474" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Inflammatory myositis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319520" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319520" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7259378" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Correlation between steroid myopathy and serum lactic dehydrogenase in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5681186" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Steroid myopathy. Clinical, histologic and cytologic observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053957" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575317" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23681396" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Predictors of self-reported health-related quality of life in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23063507" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32668290" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Rhupus: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170930" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608963" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5308132" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : "Rheumatoid" nodules in systemic lupus erythematosus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
